Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib and FOLFOX-6 in Esophageal and Gastric Cardia Adenocarcinoma
NCT00591123Phase 2Completed
- Sponsor
- TRIO
- Start
- Dec 2007
- Primary completion
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in esophageal adenocarcinoma (EAC), Gastric cardia adenocarcinoma (GCA), sponsored by TRIO. Started Dec 2007; status: completed.
02
Drugs
erlotinib
03
Conditions
esophageal adenocarcinoma (EAC)Gastric cardia adenocarcinoma (GCA)
Beyond the preview
Go deeper on NCT00591123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00591123.